🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "major milestone" in the effort against superbug strains of the bacteria, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are on the rise globally, with data suggesting in excess of 82 million infections per year. Notably increased rates are reported in Africa and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune advancement in the reality of rising global incidence, escalating drug resistance and the very limited available drugs presently on offer.”

Public health authorities are deeply concerned about the increase in drug-resistant strains. The WHO has designated it as a "high-priority threat". Ongoing monitoring found that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Gain Approval

Zoliflodacin, also known as a brand name, was cleared by the US FDA in recent days for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Researchers anticipate that specific application of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This medication, which is employed against UTIs, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a unique collaborative effort for antibiotic development. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to bring it to fruition.

“This approval marks a significant shift in the management of superbug gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Clinical Trial Results and Global Access

As per data released by a major medical journal, the new drug successfully treated the vast majority of genital gonorrhoea infections. This establishes an similar efficacy with the typical regimen, which uses two antibiotics. The research involved nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the rights to license and sell the drug in numerous regions with limited resources.

Clinicians treating patients have voiced optimism. Access to a easy-to-administer therapy like this is described as a "game-changer" for managing the epidemic. This is deemed vital to lessen the impact of the infection for people and to prevent the spread of highly drug-resistant gonorrhoea worldwide.